Taken together, our studies showed that HPS mediates lipid metabolism in human pancreas tumors, which is probably controlled by the KRAS/STAT3 signaling pathway, and EPA treatment blocks the KRAS/STAT3 pathway and HPS expression, resulting in the suppression of cell growth and survival of pancreatic cancer cells. The gene discussed is FGL1; the disease is familial pancreatic carcinoma.